Jingjing Zhao

This inventor holds 19 USPTO granted patents and 4 published patent applications and 9 EPO patents. Top assignee: Signal Pharmaceuticals, Inc.. Active years: 2012-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jingjing Zhao. Retrieved from https://idiyas.com/inventor/jingjing-zhao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 4)

% Patents Active = 100.0

EPO Patents = 9 (Patent Applications = 8)

Average Co-Inventor Count = 14.6

ph-index = 7

Forward Citations = 179(Granted Patents)

Company Filing History:

19 out of 169

Signal Pharmaceuticals, Inc.

patents

Years Active: 2012-2023

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11590139 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2023-02-28),

2. 11292796 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2022-04-05),

3. 10940152 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2021-03-09),

4. 10683298 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2020-06-16),

5. 10646493 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2020-05-12),

6. 10398700 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2019-09-03),

7. 10167290 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2019-01-01),

8. 10149849 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2018-12-11),

9. 9771371 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2017-09-26),

10. 9737541 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2017-08-22),

11. 9512124 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2016-12-06),

12. 9193692 - Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors (2015-11-24),

13. 9079900 - Methods of synthesis and purification of heteroaryl compounds (2015-07-14),

14. 8907087 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2014-12-09),

15. 8569494 - Methods of synthesis and purification of heteroaryl compounds (2013-10-29),

Title: The Innovative Contributions of Jingjing Zhao

Introduction: Jingjing Zhao is a prominent inventor based in San Diego, CA, known for his significant contributions to the field of pharmaceutical innovations. With a remarkable portfolio of 19 patents, Zhao has been at the forefront of developing novel compounds and therapeutic methods.

Latest Patents: Zhao's latest inventions include groundbreaking patents such as "Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith," which focuses on Aminopurine Compounds characterized by unique structures. Additionally, he has developed "Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors," presenting new Heteroaryl Compounds and innovative preparation methods for these compounds.

Career Highlights: As an inventor at Signal Pharmaceuticals, Inc., Zhao has played an essential role in advancing drug development and therapeutic strategies. His innovative work has not only enhanced the company's portfolio but also contributed to significant advancements in medical treatments.

Collaborations: Throughout his career, Zhao has worked alongside esteemed colleagues, including John J. Sapienza and Patrick Papa. These collaborations have fostered a dynamic environment for innovation and have enabled the development of cutting-edge pharmaceutical solutions.

Conclusion: Jingjing Zhao's dedication to innovation and his impressive number of patents underscore his significant impact on the field of pharmaceuticals. His work continues to pave the way for new treatments and therapies, reflecting the essence of progress in medical research.

Profile summary based on public USPTO records.